[HTML][HTML] Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials
SA Alomar, SA Alghabban, HA Alharbi… - Avicenna Journal of …, 2021 - thieme-connect.com
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.
S Alomar, S Alghabban, H Alharbi… - Avicenna Journal of …, 2021 - search.ebscohost.com
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials
SA Alomar, SA Alghabban, HA Alharbi… - Avicenna Journal of …, 2021 - thieme-connect.com
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.
S Alomar, S Alghabban, H Alharbi… - Avicenna Journal of …, 2021 - go.gale.com
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.
SA Alomar, SA Alghabban, HA Alharbi… - Avicenna Journal of …, 2021 - europepmc.org
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
[PDF][PDF] Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials
SA Alomar, SA Alghabban, HA Alharbi, MF Almoqati… - J Med, 2021 - researchgate.net
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials
SA Alomar, SA Alghabban… - Avicenna journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
[PDF][PDF] Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials
SA Alomar, SA Alghabban, HA Alharbi… - J Med, 2021 - quantum-genomics.com
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
[HTML][HTML] Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials
SA Alomar, SA Alghabban, HA Alharbi… - Avicenna Journal of …, 2021 - ncbi.nlm.nih.gov
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials.
SA Alomar, SA Alghabban, HA Alharbi… - Avicenna Journal of …, 2021 - europepmc.org
An unfortunate subset of hypertensive patients develops resistant hypertension in which
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …
optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control …